Diagnosis and management of hematopoietic cell transplant-associated thrombotic microangiopathy (TA-TMA) are very complex and controversial, given multiple ongoing issues and comorbidities in sick ...
Researchers discover a link between an increase in protein Ba of the complement immune system and the eventual development of thrombotic microangiopathy in patients who have received an allogeneic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SEATTLE, September 02, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival ...
— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — SEATTLE--(BUSINESS WIRE)-- Omeros ...
Omeros had submitted substantial patient-level data to CHMP in August as part of its grounds for re-examination. CHMP did not provide patient-level data to the AHEG. Narsoplimab was approved under the ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication that can occur after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Study finds that despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results